Abstract
The number of immunocompromised individuals in China is rapidly increasing, and the incidence of cytomegalovirus (CMV) infection in this population is significantly higher than in the general population, severely affecting their quality of life and prognosis. Currently, a standardized diagnostic and treatment system for refractory/resistant CMV infections in immunocompromised populations is lacking. Based on domestic and international data on the epidemiology, evidence-based medicine, and clinical research regarding refractory/resistant CMV infections, this consensus formulates recommendations for the diagnosis, treatment, and management of these infections.